Genezen Revenue and Competitors
Estimated Revenue & Valuation
- Genezen's estimated annual revenue is currently $11.9M per year.
- Genezen's estimated revenue per employee is $155,000
Employee Data
- Genezen has 77 Employees.
- Genezen grew their employee count by 0% last year.
Genezen's People
Name | Title | Email/Phone |
---|---|---|
1 | Director Human Resources | Reveal Email/Phone |
2 | Senior scientist Downstream process development SME | Reveal Email/Phone |
Genezen Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.8M | 5 | -17% | N/A | N/A |
#2 | $5.7M | 37 | 6% | N/A | N/A |
#3 | $10.2M | 66 | 6% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.6M | 49 | -2% | N/A | N/A |
#7 | $0.8M | 5 | -17% | N/A | N/A |
#8 | $7.9M | 51 | 6% | N/A | N/A |
#9 | $37.7M | 243 | -2% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Genezen?
As a premier CDMO, we provide GMP viral vector manufacturing, process development, testing, and cell manufacturing to cell & gene therapy companies.
keywords:N/AN/A
Total Funding
77
Number of Employees
$11.9M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Genezen News
2022-04-19 - Genezen fast tracks second phase expansion in US ...
Gene therapy contract development manufacturing organization (CDMO) Genezen Laboratories has completed construction of a 75,000+ square-foot...
2022-04-17 - Genezen Completes Clinical CGMP Manufacturing Facility
Genezen, a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) specializing in lentiviral and retroviral vector...
2022-04-17 - Genezen Completes Facility Buildout
Genezen, a cell and gene therapy CDMO specializing in lentiviral and retroviral vector manufacturing, completed construction of the early...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $17.5M | 77 | 8% | N/A |
#2 | $11.9M | 77 | 0% | N/A |
#3 | $20.8M | 77 | -25% | N/A |
#4 | $20.8M | 77 | 8% | N/A |
#5 | $19.3M | 77 | 5% | N/A |